Manuel M Hermann1, Freekje van Asten2, Philipp S Muether1, Dzenita Smailhodzic2, Peter Lichtner3, Carel B Hoyng2, Bernd Kirchhof1, Christian Grefkes4, Anneke I den Hollander5, Sascha Fauser6. 1. Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany. 2. Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 3. Institute of Human Genetics, Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt, Neuherberg, Germany. 4. Max Planck Institute for Neurological Research, Neuromodulation and Neurorehabilitation Group, Cologne, Germany; Department of Neurology, University Hospital of Cologne, Cologne, Germany. 5. Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 6. Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany. Electronic address: sascha.fauser@uk-koeln.de.
Abstract
PURPOSE: Intravitreal anti-vascular endothelial growth factor (VEGF) injections are currently the standard treatment for neovascular age-related macular degeneration (AMD), but a broad range of response rates has been observed. We evaluated the association of single nucleotide polymorphisms (SNPs) in VEGF genes and their receptors (VEGFR) with the response rate to ranibizumab in 366 patients with neovascular AMD. DESIGN: Case series study. PARTICIPANTS: A total of 366 eyes of 366 patients with neovascular AMD. METHODS: Visual acuity (VA) was determined at baseline, after 3 monthly ranibizumab injections, and after 1 year of treatment. Genotyping of 126 SNPs in the genes encoding VEGF family members VEGFA, VEGFB, VEGFC, VEGFD (FIGF), and placental growth factor (PGF); VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4); and the gene encoding pigment epithelium-derived factor (PEDF) (SERPINF1) was performed. MAIN OUTCOME MEASURES: The changes in VA after 3 injections and after 1 year of treatment and their association with VEGF and VEGFR genotypes. RESULTS: Univariate analyses of variance (ANOVAs) revealed a significant effect of SNP rs4576072 in the VEGFR2 gene on VA change after 12 months (F[1,235] = 14.05; P = 0.02). A stepwise linear regression analysis returned a model (P = 0.01) with SNPs rs4576072 and rs6828477 in the VEGFR2 gene as independent predictors for VA change after 12 months, with a mean increase in VA of 0.26 on the logarithm of the minimum angle of resolution (logMAR) scale in patients with 3 contributing minor alleles compared with a loss of 0.03 logMAR in patients with no minor allele. CONCLUSIONS: Polymorphisms in the VEGFR2/KDR gene significantly influence visual outcome in patients receiving ranibizumab treatment for neovascular AMD. This study shows that genetic variation partially explains the wide range of response to ranibizumab treatment, which in the future might help clinicians tailoring medical interventions to individual needs.
PURPOSE: Intravitreal anti-vascular endothelial growth factor (VEGF) injections are currently the standard treatment for neovascular age-related macular degeneration (AMD), but a broad range of response rates has been observed. We evaluated the association of single nucleotide polymorphisms (SNPs) in VEGF genes and their receptors (VEGFR) with the response rate to ranibizumab in 366 patients with neovascular AMD. DESIGN: Case series study. PARTICIPANTS: A total of 366 eyes of 366 patients with neovascular AMD. METHODS: Visual acuity (VA) was determined at baseline, after 3 monthly ranibizumab injections, and after 1 year of treatment. Genotyping of 126 SNPs in the genes encoding VEGF family members VEGFA, VEGFB, VEGFC, VEGFD (FIGF), and placental growth factor (PGF); VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4); and the gene encoding pigment epithelium-derived factor (PEDF) (SERPINF1) was performed. MAIN OUTCOME MEASURES: The changes in VA after 3 injections and after 1 year of treatment and their association with VEGF and VEGFR genotypes. RESULTS: Univariate analyses of variance (ANOVAs) revealed a significant effect of SNP rs4576072 in the VEGFR2 gene on VA change after 12 months (F[1,235] = 14.05; P = 0.02). A stepwise linear regression analysis returned a model (P = 0.01) with SNPs rs4576072 and rs6828477 in the VEGFR2 gene as independent predictors for VA change after 12 months, with a mean increase in VA of 0.26 on the logarithm of the minimum angle of resolution (logMAR) scale in patients with 3 contributing minor alleles compared with a loss of 0.03 logMAR in patients with no minor allele. CONCLUSIONS: Polymorphisms in the VEGFR2/KDR gene significantly influence visual outcome in patients receiving ranibizumab treatment for neovascular AMD. This study shows that genetic variation partially explains the wide range of response to ranibizumab treatment, which in the future might help clinicians tailoring medical interventions to individual needs.
Authors: Laura Lorés-Motta; Moeen Riaz; Michelle Grunin; Jordi Corominas; Freekje van Asten; Marc Pauper; Mathieu Leenders; Andrea J Richardson; Philipp Muether; Angela J Cree; Helen L Griffiths; Connie Pham; Marie-Claude Belanger; Magda A Meester-Smoor; Manir Ali; Iris M Heid; Lars G Fritsche; Usha Chakravarthy; Richard Gale; Martin McKibbin; Chris F Inglehearn; Reinier O Schlingemann; Amer Omar; John Chen; Robert K Koenekoop; Sascha Fauser; Robyn H Guymer; Carel B Hoyng; Eiko K de Jong; Andrew J Lotery; Paul Mitchell; Anneke I den Hollander; Paul N Baird; Itay Chowers Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389
Authors: Nathan G Lambert; Hanan ElShelmani; Malkit K Singh; Fiona C Mansergh; Michael A Wride; Maximilian Padilla; David Keegan; Ruth E Hogg; Balamurali K Ambati Journal: Prog Retin Eye Res Date: 2016-05-06 Impact factor: 21.198
Authors: Stephanie A Hagstrom; Gui-shuang Ying; Maureen G Maguire; Daniel F Martin; Jane Gibson; Andrew Lotery; Usha Chakravarthy Journal: Ophthalmology Date: 2015-05-28 Impact factor: 12.079
Authors: Margaret M DeAngelis; Leah A Owen; Margaux A Morrison; Denise J Morgan; Mingyao Li; Akbar Shakoor; Albert Vitale; Sudha Iyengar; Dwight Stambolian; Ivana K Kim; Lindsay A Farrer Journal: Hum Mol Genet Date: 2017-08-01 Impact factor: 6.150
Authors: Hironori Uehara; Christina Mamalis; Molly McFadden; Michael Taggart; Brian Stagg; Samuel Passi; Phillip Earle; Usha Chakravarthy; Ruth E Hogg; Balamurali K Ambati Journal: Am J Ophthalmol Date: 2014-10-18 Impact factor: 5.258
Authors: Un Chul Park; Joo Young Shin; Linda C McCarthy; Sang Jin Kim; Jung Hyun Park; Hum Chung; Hyeong Gon Yu Journal: Mol Vis Date: 2014-12-19 Impact factor: 2.367
Authors: Laura Lorés-Motta; Freekje van Asten; Philipp S Muether; Dzenita Smailhodzic; Joannes M Groenewoud; Amer Omar; John Chen; Robert K Koenekoop; Sascha Fauser; Carel B Hoyng; Anneke I den Hollander; Eiko K de Jong Journal: Pharmacogenet Genomics Date: 2016-01 Impact factor: 2.089
Authors: Aniruddha Agarwal; William R Rhoades; Mostafa Hanout; Mohamed Kamel Soliman; Salman Sarwar; Mohammad Ali Sadiq; Yasir Jamal Sepah; Diana V Do; Quan Dong Nguyen Journal: Clin Ophthalmol Date: 2015-06-05